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Abstract
Background: Screening programmes for tuberculosis (TB) among immigrants rarely consider the heterogeneity of
risk related to migrants’ country of origin. We assess the performance of a large screening programme in asylum
seekers by analysing (i) the difference in yield and numbers needed to screen (NNS) by country and WHO-reported
TB burden, (ii) the possible impact of screening thresholds on sensitivity, and (iii) the value of WHO-estimated TB
burden to improve the prediction accuracy of screening yield.
Methods: We combined individual data of 119,037 asylum seekers screened for TB in Germany (2002–2015) with
TB estimates of the World Health Organization (WHO) (1990–2014) for their 81 countries of origin. Adjusted rate
ratios (aRR) and 95% credible intervals (CrI) of the observed yield of screening were calculated in Bayesian Poisson
regression models by categories of WHO-estimated TB incidence. We assessed changes in sensitivity depending on
screening thresholds, used WHO TB estimates as prior information to predict TB in asylum seekers, and modelled
country-specific probabilities of numbers needed to screen (NNS) conditional on different screening thresholds.
Results: The overall yield was 82 per 100,000 and the annual yield ranged from 44.1 to 279.7 per 100,000. Country-
specific yields ranged from 10 (95%- CrI: 1–47) to 683 (95%-CrI: 306–1336) per 100,000 in Iraqi and Somali asylum seekers,
respectively. The observed yield was higher in asylum seekers from countries with a WHO-estimated TB incidence > 50
relative to those from countries ≤50 per 100,000 (aRR: 4.17, 95%-CrI: 2.86–6.59). Introducing a threshold in the range of a
WHO-estimated TB incidence of 50 and 100 per 100,000 resulted in the lowest “loss” in sensitivity. WHO’s TB prevalence
estimates improved prediction accuracy for eight of the 11 countries, and allowed modelling country-specific probabilities
of NNS.
Conclusions: WHO’s TB data can inform the estimation of screening yield and thus be used to improve screening
efficiency in asylum seekers. This may help to develop more targeted screening strategies by reducing uncertainty in
estimates of expected country-specific yield, and identify thresholds with lowest loss in sensitivity. Further modelling
studies are needed which combine clinical, diagnostic and country-specific parameters.
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Background
Systematic screening for tuberculosis (TB) is the “[…]
systematic identification of people with suspected active
TB in a predetermined target group by the application
of tests, examinations or other procedures […]” [1]. In-
dependently of the accuracy of the applied diagnostic
test, the prevalence of active TB in the screened popula-
tion is a key determinant of yield, numbers needed to
screen (NNS) to identify one case of TB and predictive
values of screening tests [2].
Asylum seekers and refugees are considered at high
risk for TB infection and disease [3], mainly due to pre-
and peri-migration factors favouring the transmission or
re-activation of TB [4, 5]. Therefore, the majority of
European countries have implemented systematic
screening programmes for this group of migrants [6–8].
Screening practices among asylum seekers and refugees
in Europe mostly comprise chest radiography (CXR)
alone or combined with other diagnostics [9]. The over-
all yield of screening for active TB in asylum seekers
upon-entry has been estimated to be about 0.28% in a
meta-analysis of international studies [3] and about
0.35% in a meta-analysis of studies from Germany [10].
Although TB screening in asylum seekers is recom-
mended [5, 11], there are concerns about effectiveness
[12, 13] and costs of TB screening programmes [6, 14].
Asylum seekers are a risk group with high heterogeneity
with respect to their individual constituencies and coun-
tries of origin [15, 16]. Screening in asylum seekers is
usually not targeted, i.e. performed in a stratified manner
according to risk-groups within this population.
Evidence-based screening strategies which take the het-
erogeneous distribution of risk into account could help
finding the same or sufficiently high number of cases
using fewer resources and thus improve screening effi-
ciency. This would be desirable especially in times of high
immigration to countries with a low incidence of TB [15].
A pre-migration factor shown to affect the yield of
screening in migrant populations, and thus screening
efficiency, is the burden of TB in the country of origin
[17]. However, although studies report country-stratified
yield of screening in general migrant groups [17, 18],
only few empirical studies have reported the yield of
screening in asylum seekers stratified by country of ori-
gin [3, 10, 16]. The presumed link between asylum
seekers’ country of origin and performance of screening
programmes is suggested by clinical experience and de-
scriptive epidemiological reports comparing the TB
prevalence in the country of origin with the observed
screening yield in asylum seekers. Examples are studies
conducted in the Netherlands [19] and Germany [10]
which compared yield of screening with TB prevalence
in the country of origin reported by the World Health
Organization (WHO). More analytical approaches to
guide the choice of TB screening strategies have yet ex-
clusively focused on clinical and diagnostic parameters
[2], or have considered the role of country of origin but
have been conducted among general migrant groups in
the context of latent TB [18]. As a consequence,
evidence-based guidance to inform the development of
targeted screening in the heterogeneous groups of asy-
lum seekers with respect to their country of origin is
lacking. Specifically, the predictive value of asylum
seekers’ country of origin for the yield of screening
remains uncertain as the association between country of
origin and expected yield of screening is not fully
established.
We here present a modelling study to inform the de-
velopment of targeted screening strategies in asylum
seekers using individual and population-based parame-
ters related to asylum seekers’ country of origin. We hy-
pothesise that country of origin linked with information
on TB burden in asylum seekers’ country of origin can
be used to improve screening efficiency. Using screening
data of a large German federal state, we aimed to assess
the performance of the screening programme over a lon-
ger time-period with changing migration intensity. We
analyse (i) the difference in yield and NNS depending on
country of origin and WHO-estimated TB incidence in
asylum seekers’ country of origin, (ii) the possible impact
on sensitivity of screening when introducing a screening
threshold, and (iii) the value of WHO-estimated TB
prevalence to improve prediction accuracy of yield and
therefore screening efficiency in asylum seekers.
Methods
Source of screening data
We used data from mandatory upon-entry screening
for TB in asylum seekers between 2002 and 2015 from
the main reception centre of the third largest federal
state in Germany with about 10 million inhabitants
(Baden Württemberg). The reception centre quasi-ran-
domly received about 13% of newly arriving asylum
seekers to Germany based on administrative quota. All
newly arriving asylum seekers are registered with a
unique identification number and are required to
undergo a mandatory health examination according to
national law [20] (§62 of the Asylum-Law in combin-
ation with §36 of the Infection Protection Act).
Screening protocol
The health examination consists of symptom-based
screening for all asylum seekers to identify communic-
able diseases and a compulsory chest X-ray (CXR)
examination for all asylum seekers above 15 years
(except pregnant women) regardless of the results of
symptom-based screening. The protocol for children
below 16 years consisted of a tuberculin skin test
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(2002–2010) and symptom-based screening (2011–
2015). Pregnant women underwent screening for TB
infection either by a tuberculin skin test or
interferon-gamma release assay (IGRA) (2002–2015).
For non-pregnant adults, the screening is not sequen-
tial and CXR can be regarded as the first screening
test. Asylum seekers with presumptive TB undergo
further diagnosis by means of a facultative chest com-
puter scan, a sputum test (microscopy or PCR) and
culture tests. Ultimately, an active TB case was defined
by the fact that the physician decided to start treat-
ment (including clinically diagnosed cases,
smear-positive cases and/or culturally confirmed TB).
Asylum seekers must reside in the reception centre
until the final result of the mandatory TB screening is
obtained and they are not transferred to counties and
communes unless active TB is ruled out. Those diag-
nosed with active TB are put on treatment in a hos-
pital setting and not transferred unless risk of
transmission has been ruled out. Further details of the
screening protocol (e.g. for children < 16 years and
pregnant women) are provided elsewhere [15].
Data source for TB in asylum seekers’ country of origin
Estimates for TB incidence and prevalence (per 100,000
population) in asylum seekers’ countries of origin were
taken from the WHO Global Burden of TB database
[21]. Following classifications used by the European
Centre for Disease Prevention and Control [22] and de
Vries et al. [19, 23], we classified asylum seekers’ coun-
tries of origin as low-, intermediate-, or high-incidence
country when its WHO estimated period-averaged
(1990–2014) TB incidence (Additional file 1) ranged be-
tween 0 and 20, between 21 and 50, or > 50 per 100,000,
respectively. This classification was used to calculate the
proportion of asylum seekers in the screening data
stemming from countries with a low or intermediate
incidence of TB among the total population of asylum
seekers screened in each year. Further categories with
higher cut-offs coded as binary variables (≥ 100, ≥ 150,
≥ 200, ≥ 250 and ≥ 300 per 100,000, respectively) were
additionally used for both descriptive and analytical
purposes. We further used data on TB prevalence (all
forms, per 100,000 population) from WHO as external
(“prior”) information for a set of 11 countries for which
it was possible to calculate the country-specific
observed yield from the screening data with reasonable
precision (see below for details).
Statistical analysis
We assessed the period-, country-specific and the annual
yield of TB screening as well as the NNS to identify one
case of TB in the German screening data as defined in
Table 1.
Throughout, we adopted a Bayesian perspective, thus
treating parameters as random variables and considering
prior information (see also Table 1 for further details)
[24]. To investigate the performance of the screening
programme and the suggested link between TB burden
in the country of origin and the yield of screening in
asylum seekers, we applied four main strategies:
1. We assessed the change over time in number of TB
cases, yield per 100,000 asylum seekers, proportion of
asylum seekers from low- and intermediate-incidence
TB countries, and number of asylum seekers
screened. We further plotted country-specific yield
of screening against the number of asylum seekers
screened in each category of country, stratified by
the above classification based on WHO data in
low−/intermediate- vs. high-incidence TB country.
2. We used Bayesian Poisson Regression with age, sex,
year of screening and WHO-estimated incidence
of TB (dummy: high vs. low and intermediate TB
incidence) as individual-level predictors to analyse
the age- and sex-adjusted difference in the yield of
screening (2002–2015) between asylum seekers
from countries with a WHO-estimated low and
intermediate incidence of TB and those with a high
incidence of TB. Flat priors were applied for all
effects and the models were fit in Stata (version 14)
using the Metropolis-Hastings algorithm. Five
additional models with higher cut-offs of WHO-
estimated incidence of TB (≥ 100, ≥ 150, ≥ 200,
≥ 250, and ≥ 300 per 100,000) were used while
adjusting for the same co-variables.
3. We used period-averaged (1990–2014) WHO esti-
mated TB incidence with their corresponding
period-averaged 95% confidence intervals (Add-
itional file 2) to calculate the impact on sensitivity
of screening by introducing a screening threshold
at any given value of WHO data. To this end, the
number of false negative TB cases, the number of
individuals not screened, and the number of false
negative TB cases per 1000 individuals not
screened was calculated and plotted depending on
any given threshold
derived from WHO data.
4. We hypothesised that TB prevalence estimates
from WHO may be valuable prior information that
allows improved predictions of screening yield for
each single country. This is naturally accommodated
under a Bayesian perspective. We assumed an
informative prior distribution for the prevalence of
TB in different countries on the basis of WHO data.
After descriptively comparing the yield by country of
origin from the screening data with the prevalence of
TB in respective countries of origin based on WHO
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data (Additional file 1: Figure S1,), we employed a
statistical model and combined the two data sources
(WHO data and screening data) for predictions of
yield and NNS using the R language and environment
for statistical computing [25]. Finally, we provide an
empirically derived overview of country-specific
probabilities of NNS to assess the impact on
screening efficiency when using different
thresholds for screening.
Comparison of country-specific yield with country-level
WHO estimates of TB prevalence
To compare the country-specific yield of TB in asylum
seekers screened in Germany (2002–2015) with country-
level WHO estimates of TB prevalence reported in the
WHO global TB database (1990–2014), we chose coun-
tries based on following criteria: ≥ 5 cases identified dur-
ing screening or ≥ 5000 asylum seekers screened, and
availability of country-level estimates in the WHO global
TB database. The determination was deemed to allow
estimation of screening yield and regression model
parameters with reasonable precision and resulted in a
manageable set of countries for reporting of stratified
analyses. Eleven countries in the screening data source
fulfilled the two criteria: Afghanistan, Cameroon, Eritrea,
Gambia, Georgia, Iraq, Macedonia, Pakistan, Russia,
Somalia and Syria.
We then determined the prior distribution based on
the WHO estimates for the TB prevalence of each coun-
try and year (Table 1) and obtained the posterior distri-
bution for TB prevalence, interpreted as expected TB
prevalence, based on the combined data. This expected
TB prevalence was used to calculate the probability that
the NNS of a certain country is above a given cut-off
value t in order to inform the choice of thresholds for or
against TB screening based on asylum seekers’ country
of origin (Table 1).
Sensitivity analysis
We performed a sensitivity analysis using the most re-
cent TB estimates for the year 2015 of the global burden
of disease (GBD) study [26] as prior information instead
of WHO estimates (see Additional file 1 for details).
Table 1 Outcomes measures, analytical perspective and statistical methods
Yield of TB screening:
The fraction of active TB cases detected among the number of asylum seekers actively screened for TB, expressed as cases per 100,000 persons.
Number needed to screen (NNS):
The number of asylum seekers that need to undergo screening in order to diagnose one person with active TB [13], calculated as the inverse
of yield.
Bayesian perspective:
Bayesian estimation and inference generally differ from frequentist methods that are still mostly seen in clinical and public health research in treating
parameters as random variables (as opposed to constants in frequentist methods) [24]. The learning process in Bayesian methods works by modifying initial
probability statements about parameters (prior distributions) before observing the data to updated or posterior knowledge that combines both previous
knowledge and the data at hand. It allows hypotheses to be assessed by using a collection of parameter samples from their posterior distribution. A main
advantage of Bayesian methods is the probabilistic (more common sense) interpretation of the confidence interval, here termed credible interval (CrI) on
parameters. Key ingredients of a Bayesian statistical model are the likelihood function, reflecting information about the parameters contained in the data,
and the prior distribution, quantifying what is known about the parameters before observing data. The prior distribution and likelihood can be combined to
the posterior distribution, which represents total knowledge about the parameters after the data has been observed in the following sense [38]:
posterior∞ prior × likelihood,
where ∝ means “is proportional to”. When considering the occurrence of a TB case in the screening process as “success” in n independent trials, the
prevalence may be modeled to be binomially distributed. We exploit here that the conjugate prior for the binomial distribution is the beta
distribution (Additional file 1).
Determination of prior distributions using WHO data:
WHO reports indirect estimates with a 95% CrI, except for Gambia and Pakistan where estimates are based on population-based surveys. This information
was used to derive a Beta(p;q) prior distribution for the TB prevalence (Additional file 1: Figure S2). According to the method of moments [39] the shape
parameters p and q of the beta distribution Beta(p;q) were estimated on the basis of the WHO data as follows:
p∧ ¼ ð1 − pσ2 − 1pÞ p2 and q̂ ¼ p̂ ð1p − 1Þ,
where p is the mean prevalence (averaged over the years 1990 to 2014) for each country and σ is the mean standard deviation. The mean standard
deviation σ is computed on the basis of the lower and upper bounds of the 95% credible intervals given by the WHO data for each country and
year. It is assumed that:
width (95 % credible interval) ≈ 2 × 1.96 σ, and therefore mean ðwidth ð95%credible intervalÞÞ21:96 ≈ σ.
This gives a Beta(p̂; q̂) distribution for each country.
Modelling country-specific probabilities of the NNS to lie above a given cut-off value
The probability that the NNS for a certain country is above a given cut-off value t can be calculated from the derived posterior distributions of the
prevalence in each country as follows: First, we use the inverse of the expected prevalence as NNS, and then we calculate the cumulative distribution
function of the prevalence at 1/t.
P ½NNS ≥ t ¼ P ½ 1expected prevalence ¼ NNS ≥ t
¼ P ½expected prevalence ≤ 1t
¼ F ð1tÞ
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Results
Data on 119,037 asylum seekers from 81 countries with
a median age of 24 years were available (interquartile
range: 14 years) (Table 2). A total of 98 cases of pulmon-
ary active TB were identified in the scope of upon-entry
screening in the observation period over 14 years corre-
sponding to an overall yield of 82 (68 to 100) per
100,000 and an overall NNS of 1215 (996 to 1480). The
majority of asylum seekers (62.2%) were from a total of
seven countries of origin. Of the 98 active TB cases,
69.3% were detected in asylum seekers from nine coun-
tries of origin (11.1% of all countries). More than three
quarters of TB cases were identified in asylum seekers
from countries with a WHO-estimated high incidence of
TB (Table 2).
Country-specific yields were highest for asylum
seekers from Somalia (lowest NNS) and lowest for asy-
lum seekers from Iraq (highest NNS). With the excep-
tion of 2014, a lower yield of screening (and a higher
NNS) was observed in 2013 and 2015 compared to the
preceding time period (2002–2012), indicating a de-
crease in screening efficiency. Further details of yield
and NNS with corresponding CrIs by age, sex, period,
country of origin, and WHO category of estimated inci-
dence of TB are presented in Fig. 1a and b (underlying
data is provided in Additional file 3).
Change in screening performance and the screened
population over time
The annual yield varied considerably in the observation
period and ranged from 44 to 279 per 100,000 asylum
seekers (Fig. 2a). The proportion of asylum seekers from
low- and intermediate-incidence TB countries among
the screened population ranged from 32.6% in the year
2004 to 65.4% in 2015 (Fig. 2b). Compared to the index
year 2002, the number of asylum seekers screened in
2015 increased more than 10-fold, TB cases (2015) by
333%, and the proportion of asylum seekers from low-
and intermediate-incidence TB countries by 38.2%, while
the yield (per 100,000) decreased by 62.3% (Fig. 3).
Difference in observed yield of screening based on WHO-
estimated incidence of TB
The annual proportion of asylum seekers from low- and
intermediate-incidence TB countries among the screened
population was negatively correlated with annual TB yield
(rho: − 0.08). The overall yield of TB in asylum seekers
from countries with a WHO-estimated high incidence of
TB was 4.17 times the yield in those from countries with a
low and intermediate incidence of TB, adjusted for age,
sex and period effects (Table 3).
The difference in observed yield among asylum
seekers from different countries of origin decreased
gradually when higher cut-offs of WHO-estimated
Table 2 Characteristics of the study population and TB cases
by age group, sex, year and selected countries of origin,
N = 119,037
Characteristic N %a Cases with active TB detected %a
Age groupb
< 15 years 24,249 20.4 4 4.1
15–24 years 35,390 29.8 35 35.7
25–44 years 51,111 43.0 56 57.1
45–64 years 7583 6.4 3 3.1
> 64 years 616 0.5 0 0.0
Missing data 88 0.1 0 0.0
Sex
Female 36,872 31.0 13 13.0
Male 82,051 68.9 85 85.0
Missing data 114 0.1 2 2.0
Year
2002–2012 36,647 30.8 41 41.8
2013 14,407 12.1 7 7.1
2014 23,916 20.1 24 24.5
2015 44,067 37.0 26 26.5
Countrya
Afghanistan 7433 6.2 2 2.0
Cameroon 2506 2.1 5 5.1
Eritrea 1941 1.6 9 9.2
Gambia 6971 5.9 18 18.4
Georgia 2121 1.8 5 5.1
Iraq 9955 8.4 1 1.0
Kosovo 20,336 17.1 7 7.1
Macedonia 7005 5.9 2 2.0
Pakistan 5103 4.3 7 7.1
Russia 3026 2.5 5 5.1
Somalia 1025 0.9 7 7.1
Syria 17,172 14.4 5 5.1
Other 32,401 27.2 24 24.5
Missing data 2042 1.7 1 1.0
WHO-estimated incidence of TB in country of origin (per 100,000), N =
116,995c
≤ 50 66,735 57.0 21 21.6
> 50 50,260 43.0 76 78.4
≥ 100 40,908 35.0 67 69.1
≥ 150 35,395 30.3 61 62.9
≥ 200 19,028 16.3 32 33.0
≥ 250 11,839 10.1 19 19.6
≥ 300 4717 4.0 4 4.1
aCountries with either ≥5 cases of active TB detected or more than 5000 individuals
screened, all others classified as “other”. Abbreviations: TB, tuberculosis a Column
percent per characteristic; b Mean age [standard deviation]: 24.7 [13.0]. c Difference
to N= 119,037 due to missing data on country of origin for n= 2042 individuals
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incidence of TB were used to determine comparison
groups (Fig. 4).
Comparison of country-specific observed yield with WHO
estimates of TB
The estimated yield of screening in asylum seekers
from the majority of countries was generally below
200 per 100,000, except for Cameroon, Georgia,
Gambia, Sudan, Vietnam, Eritrea and Somalia. A con-
siderable number of individuals, up to 10,000 and
more asylum seekers from Iraq, Syria and the Kosovo
respectively, were screened with a relatively low yield
of TB (Fig. 5).
The WHO-estimated country-level prevalence of TB
was close to the observed country-specific period yield
of screening (2002–2015) in asylum seekers from
Cameroon, Georgia, Russia, Somalia and Macedonia
(Additional file 1: Figure S1). The observed period yield
of screening was higher than the reported WHO estimates
for asylum seekers from Eritrea and Gambia, while for
a
b
Fig. 1 Yield and number needed to screen with credible intervals by age, sex, period, country of origin and WHO category of estimated incidence TB,
N = 119,037 asylum seekers, 2002–2015, Germany. Legend: a Yield; b Number needed to screen, NNS. Y-Axis: log-scale. Plot size shows numbers of
individuals screened
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asylum seekers from Afghanistan and Iraq the observed TB
yield was lower (Additional file 1: Figure S1).
Impact on sensitivity of screening depending on
screening thresholds
Introducing a threshold for screening to increase the
pre-test probability would lead to “missed” TB cases (i.e.
false negative individuals), and the absolute number
would increase with rising screening threshold (Fig. 5a).
For example, a threshold of 50 per 100,000 based on
WHO-reported incidence of TB would lead to 21 (22%)
undetected TB cases (Fig. 6a). However, a total of about
66,700 individuals would be exempt from screening at
this threshold (Fig. 6b), corresponding to about 0.3 un-
detected TB cases per 1000 individuals not screened
(Fig. 6c). Considering the time period (13 years), the rate
of false negatives at this threshold corresponds to 2.4
undetected TB cases per 100,000 individuals per year.
Increasing the threshold up-to 100 per 100,000 would
lead to a marginal increase in the number of undetected
TB cases per 1000 individuals, but higher thresholds
come along with a higher number of undetected cases
per 1000 and entail a much larger trade-off between gain
in pre-test probability and loss in sensitivity (Fig. 6c).
Comparison of prior distribution, data likelihood and
posterior distribution
Comparison of the different distributions of observed
country-specific yield and WHO-estimated TB preva-
lence showed that the use of the prior information re-
sulted in narrower density distributions of the posterior
distribution and thus improved prediction for eight of
the eleven countries (Fig. 7). For three countries
(Afghanistan, Eritrea and Iraq) the agreement between
WHO and the screening data appeared to be smaller
than for the remainder of countries.
Consequences for screening efficiency when using
different NNS cut-offs for screening
To use this information for predictions of screening effi-
ciency, we plotted the probability to lie above a given
NNS value (ranging from 0 to 50,000) for each country
(Fig. 8). This showed that, for example in asylum seekers
from Iraq, Macedonia and Syria, the probability is more
than 80% that the NNS is higher than 2000 (a threshold
that has been used in the Netherlands and Finland to de-
cide whether or not screening should be initiated [8, 19]).
The probability that the NNS is higher than 500 is less
than 10% for asylum seekers from Cameroon, and close to
zero for asylum seekers from Pakistan and Somalia. The
expected screening efficiency in a given population can
thus be estimated based on different NNS cut-offs.
Sensitivity analysis
Using GBD estimates of TB prevalence instead of WHO
data as prior improved the prediction of TB only for three
countries (Eritrea, Iraq, and Pakistan). In the sensitivity
analysis, the German screening data had little influence on
the posterior distribution (Additional file 1: Figure S3,)
and the GBD priors had substantially higher influence on
the posterior distribution due to their considerably nar-
rower uncertainty bounds (Additional file 1: Figure S4).
Discussion
This study provides evidence that age- and sex-ad-
justed yield of screening for TB and corresponding
NNS to identify one case of TB among asylum seekers
vary strongly depending on country of origin. The
Fig. 2 Absolute number of TB cases, yield of screening, and proportion of asylum seekers from low- and intermediate-incidence TB countries, N= 119,037
asylum seekers, 2002–2015, Germany. Legend: a Absolute number of TB cases and yield of screening by year; b proportion of asylum seekers from low-
and intermediate-incidence TB countries by year
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dynamic changes in the population screened have im-
plications for the performance of screening pro-
grammes, as shown here by higher NNS and lower
yield after 2012 compared to preceding time periods.
Being able to account for the composition and to react
to possibly rapid changes in the population of asylum
seekers and to corresponding TB risks is crucial for a
responsive and efficient screening programme, but an
adequate evidence base is required to guide decision
making. We have shown that WHO-reported TB inci-
dence is a predictor of observed yield as the age- and
sex-adjusted risk of TB in asylum seekers from coun-
tries with a high incidence of TB (> 50 per 100,000) is
about four times of those from countries with a low
and intermediate incidence (≤ 50 per 100,000). These
findings are consistent with other studies on TB in mi-
grant populations [27, 28], although direct comparabil-
ity may be limited due to differences in migrant
populations, screening protocols, timing of screening,
and differences in (or lack of ) adjustment strategies in
other studies. The discriminatory power of country of
origin to determine groups of asylum seekers with higher
observed yield, however, decreased with rising cut-offs
above 100 per 100,000 (based on WHO-estimated inci-
dence of TB). This is consistent with our data showing
how introducing a threshold for screening to increase the
pre-test probability affects the sensitivity of screening pro-
grammes. This study thus provides a useful first evidence
base for decision-making with respect to the development
of targeted programs.
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Asylum seekers’ country of origin can inform TB
screening strategies in mainly two ways. First, country-
specific TB data can be used to meaningfully categorise
the population to be screened according to the TB inci-
dence in their country of origin. This information may
help public health practitioners and health planners to
anticipate the consequences of changes in the compos-
ition of the screened population on screening efficiency
in order to react to underlying population dynamics
among asylum seekers (and eventually other forced mi-
grants). It may also help to prioritise asylum seekers
from specific countries of origin for screening in times
of high immigration in order to allocate scarce re-
sources efficiently and avoid likely unnecessary diag-
nostics among groups of asylum seekers with low yield.
The categories, however, are crude classifications, and
reliance on WHO data alone may be misleading espe-
cially in fragile states or countries hit by armed con-
flicts. Reducing uncertainty in decision-making is thus
desirable.
We show that, second, combining WHO TB prevalence
data as prior information with information on observed
yield from historical TB screening data reduced uncer-
tainty of predictions. This approach allowed modelling the
expected country-specific yield of TB (posterior distribu-
tion) in asylum seekers from 11 countries with greater
precision. This information can be practically useful to de-
rive country-specific probabilities for the NNS conditional
on a given threshold to inform TB screening programs or
guide cost-effectiveness analysis.
Table 3 Difference in yield of screening in asylum seekers from countries depending on the WHO-estimated incidence of TB in their
country of origin, adjusted for age, sex, and period-effects, 2002–2015, Germany, N = 116,813
Predictor Rate Ratio (95% CrI)
Country of origin with a WHO-estimated high incidence of TB (> 50 per 100,000) (Reference: Country of origin with a WHO-
estimated low and intermediate incidence of TB (≤ 50 per 100,000)).
4.17 (2.86, 6.59)
Age (years) 1.02 (1.00, 1.03)
Female (vs. male) 0.44 (0.26, 0.72)
Period (Reference: 2002–2012)
2013 0.43 (0.20, 0.83)
2014 0.96 (0.62, 1,49)
2015 0.69 (0.44, 1.1)
CrI credible interval, TB tuberculosis. Difference in observations to N = 119,037 are due to a complete case analysis and missing data for country of origin (n = 2042), age
(n = 88), sex (114). Bold figures: 95% CrI larger or smaller than 1
Fig. 4 Difference in yield of screening in asylum seekers from countries depending on the WHO-estimated incidence of TB in their country of
origin, adjusted for age, sex, and period-effects, 2002–2015, Germany, N = 116,813. Legend: Cut-off: Derived from WHO-estimated incidence of TB
per 100,000. RR: Relative rate. CrI: Credible interval. Estimates derived from five distinct multiple Bayesian Poisson regression models. The reference
group for each cut-off (e.g. ≥ 150) is the group of asylum seekers from countries with values of WHO-estimated TB incidence lower than the
respective cut-off (e.g. < 150)
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Implications for screening programmes
Only few countries perform targeted screening based
on TB incidence in the country of origin (e.g. the
United Kingdom and Switzerland), and incidence
thresholds at which screening is initiated vary, ran-
ging from > 15, > 40, > 50 to > 100 per 100,000
population [4, 8]. In Germany, no targeted approach
exists and all migrants in collective accommodation
centers aged 16 years and above undergo compulsory
screening (except for pregnant women and children
who may be considered for screening based on
sub-national regulations [29]). The results of our study
question such indiscriminate screening policies. Other
countries use NNS thresholds to decide whether or not to
continue or discontinue screening in a given population. In
the Netherlands, for example, screening is ceased at an esti-
mated NNS > 2000 [19]. These thresholds are, however, to
a certain degree arbitrary and based on practical experience
and the question is how to best choose a threshold. Making
decisions about targeted screening programmes requires
that questions around sensitivity, timing of screening, and
efficiency and cost-effectiveness are addressed.
Our study provides an empirically derived alternative
to previous decision-making for or against screening in
this context. Limiting screening to a smaller fraction of
asylum seekers will, by necessity, miss some rare cases
originating from low-incidence countries. The important
normative question at the societal or health system level
is therefore what is valued as a good or acceptable bal-
ance between sensitivity of screening and efficiency and
cost-effectiveness of screening. Introducing a threshold
means to abandon the traditional idea that entry screen-
ing should detect all TB cases among migrants, which is
likely to be an inefficient and perhaps also an unrealistic
target. Based on the analysis of change in sensitivity
when increasing the pre-test probability, our data sug-
gests that a threshold, based on WHO-reported TB inci-
dence between 50 and 100 per 100,000, would entail the
lowest trade-off between loss in sensitivity and efficiency
of screening. When introducing a screening threshold at
50 per 100,000, the number of false negative individuals,
i.e. asylum seekers with TB going unnoticed, per 1000
individuals is relatively low (although it cannot be ruled
out that these would have been also identified due to
clinical symptoms or contact investigations). While
screening all individuals upon-entry is an approach that
might be feasible in times of low immigration, it is tech-
nically, practically, ethically, and economically question-
able, especially in times when numbers of immigrants
peak. Passive case finding approaches and improved ac-
cess to primary care [30] could complement a targeted
approach at such a threshold to ensure that the few
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individuals with TB among those exempt from screening
are noticed as soon as an infection turns into disease
and becomes symptomatic. If the purpose of a
programme is to increase efficiency, the threshold could
probably be even increased to 100 per 100,000 without
substantial loss in sensitivity.
Furthermore, the estimated country-specific proportion
of detected TB cases conditional on NNS-based cut-offs
allows assessing the impact on screening efficiency when
using different NNS thresholds for screening of asylum
seekers from a given country. The data provided by our
study can be used to calculate such targets and estimate
marginal costs of finding additional TB cases in asylum
seekers from low-incidence countries to guide such deci-
sions. Even with universal screening and more if screening
is selective, the country has to expect that some TB cases
will be undetected and will appear after entry. Research in
a large cohort of immigrants to the United Kingdom has
shown that the risk of TB incidence among immigrants
screened negative before entry is highest during the first
two to 4 years after immigration [17]. Furthermore, the
proportion of cases detected before entry are relatively
low compared to those developing TB after immigration
[17]. Data from Germany is consistent with these findings,
showing that cases detected upon entry are only a small
fraction of cases becoming incident in the following years
[31]. Providing universal access to health care and social
protection [32] and complementing targeted upon-entry
screening with adequate (i.e. culturally, ethically and eco-
nomically acceptable) programmes for post-migration
follow-up for TB [16, 33] is thus of crucial importance,
also for TB control in Germany.
Our study adds further complexity to the question
of “pre-entry, post-entry or no tuberculosis screening”
[11] among immigrants by considering asylum seekers
as a socially constructed, heterogeneous group [16].
Asking whom to screen among asylum seekers instead
of whether or not to screen [11] all would be of spe-
cial importance for countries at the external borders
of the EU such as Italy, Greece and Spain with a high
number of forced migrants arriving every year. These
countries currently apply an ‘all or nothing principle’
with respect to TB screening (Greece and Spain ac-
tively screening all, and Italy none of the incoming
refugees [8, 9]). A more nuanced approach would
consider the expected TB prevalence based on asylum
seekers’ countries of origin. Such an approach should
be closely linked with the question of the design and
a b c
Fig. 6 Impact of screening thresholds on sensitivity of screening, N = 116,995 asylum seekers, 2002–2015, Germany. Legend: a) Undetected cases
of TB, b) Individuals not screened, c) Undetected TB cases among individuals not screened (per 1000), X-axis: Cut-off based on WHO-reported TB
incidence per 100,000. Dotted lines: Cut-off calculated based on lower and upper bound of 95% confidence intervals reported by WHO. Difference to
N=119,037 due to missing information on country of origin among =2042 asylum seekers
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optimal timing for post-migration follow-up [17, 33]
screening for asylum seekers from countries at high-
est risk for TB [16].
Beyond efficiency, our study has also implications with
respect to equity and ethical aspects. Screening strat-
egies that take into account country-specific risk avoid
overprovision of services [34], allow to allocate resources
where needs are highest (vertical equity), and are there-
fore an essential step towards tailored and appropriate
high-value care [35, 36] for asylum seekers. Targeted
screening is, however, a double-edged sword. Ethical im-
plications from strategies targeting asylum seekers based
on country of origin are to avoid stigmatisation. This re-
quires that clinicians, policy makers, politicians and pub-
lic health services effectively communicate the fact that
these groups area “at higher risk” of having TB, not “a
higher risk” for importing TB [37].
Future research
Prediction algorithms for targeted screening could be
further improved by combining clinical, diagnostic
[2, 13] and country-specific parameters. A combin-
ation with age, sex and socioeconomic status could
further improve estimates of expected yield. This is
especially relevant to further decrease the potential
loss in sensitivity, and reduce the trade-off between
sensitivity and high pre-test probability. Clinical in-
formation on co-morbidities (e.g. HIV, or diabetes)
and socioeconomic factors were, however, not avail-
able in our data. The empirical derivation of such
algorithms and their validation is further compli-
cated because TB is a rare disease (thus, large sam-
ples are required) and available data often contain
little detail on personal characteristics. We were able
to estimate parameters for only 11 of 81 countries
with reasonable precision. Pooling of large datasets
across countries with comparable screening protocols
is needed to enable further data analysis, especially
as the overall yield in our study was lower than
those reported in other studies on asylum seekers [3,
10]. This would allow replicating and applying our
approach to other countries of origin. Initiatives
such as the E-DETECT TB project co-funded by the
European Commission [8] may be instrumental to
this end. Furthermore, cost-effectiveness studies
based on the data on thresholds and NNS provided
in this study, or in studies with a larger sample size
with more TB cases could be performed to generate
further guidance for the decision-making towards
targeted screening programmes.
Strengths and limitations
We used a mono-centric data source spanning 14 years
of upon-entry TB screening in one of the largest Ger-
man federal states, which is comparable in size and
population to Belgium or the Netherlands. The sample
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Fig. 7 Densities of the prior distribution on the basis of the WHO
data, the binomial distribution on the basis of the German screening
data and the density of the posterior beta distribution of the
prevalence for each country
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can be seen as representative with respect to age and sex
distribution for asylum-seekers in Germany. The com-
position of the target population with respect to coun-
tries of origin may vary between federal states due to
administrative procedures in the asylum process. How-
ever, this variation affects only few countries of origin,
and the majority of asylum seekers are distributed to
federal states based on a quasi-random administrative
process [29]. It is hence likely that the composition of the
population over 13 years resembles those of Germany as a
whole, although direct comparison with administrative
data provided by the Federal Agency for Migration and
Refugees is difficult.
We only focused on active TB cases as the primary
aim of upon-entry screening is to avoid transmissions in
asylum seekers’ shelters. Including asylum seekers with
latent TB in the analysis would have increased the yield
estimates, but would have been less relevant for inform-
ing screening programmes.
Despite the large sample used the generalizability to
other EU countries may be limited due to the heterogen-
eity in screening protocols [8]. It may also be the case
that countries of first arrival of asylum seekers in South-
ern Europe have different (and higher) screening yields.
However, we are not aware of any systematic analysis of
differences in screening yield depending on the migra-
tion trajectory.
Given the low yield of TB screening and the uncer-
tainty around estimates of observed screening yield,
external evidence on TB burden should generally be
considered in decisions for or against screening of asy-
lum seekers from a given country since the uncertainty
can be reduced. Depending on the general agreement
between prevalence in country of origin and empirical
screening data this may be sensible for some countries
(e.g. Syria), but not for all countries (e.g. Afghanistan). It
generally appears sensible where no or very sparse evi-
dence exists from screening studies, where estimated TB
prevalence and observed screening yield are not in con-
flict, and where no evidence exists that the screened
population is substantially different from the general
population with respect to TB risk. It might be sensible
to add some “extra-uncertainty” to the country-specific
prior (i.e., not applying the prevalence as the prior distri-
bution 1:1 but to make it less informative) to consider
the possibility that asylum and general populations differ
with respect to TB risk. We have shown that WHO data
is more reasonable to use as prior information instead of
GBD estimates. The uncertainty in WHO data is a study
limitation, and using period-averaged estimates as proxy
of country-specific TB risk may not reflect the “true” risk
at time of emigration. But this approach seemed as both
practicable and reasonable for the vast population in our
sample. Although GBD estimates appear more robust,
and thus intuitively better, their narrow uncertainty
bounds imply such a high certainty that no other source
of information (in this case observed TB prevalence
taken from screening data) was able to influence the dis-
tribution of data. This was not unproblematic as the de-
viance between observed screening data and prior
information was higher for GBD data than for WHO
data. The reason for this may be the use of period preva-
lences for both WHO (1994–2014) and German screen-
ing data (2002–2015), while using point prevalences
(2015) for GBD data.
Conclusion
Information on TB in the country of origin of asylum
seekers can guide the choice of screening thresholds. A
threshold based on WHO-reported incidence between
50 and 100 per 100,000 increases the pre-test probability
(and screening efficiency) substantially while keeping the
loss in sensitivity at an acceptable level. Consideration of
WHO data on TB prevalence in the country of origin of
asylum seekers can further improve the precision of esti-
mates of screening yield. This helps to reduce uncer-
tainty in making an informed decision for or against TB
screening in asylum seekers from a given country, and
allows to model country-specific NNS thresholds. We
Fig. 8 Plot of the probability that the posterior distribution of
expected TB prevalence in asylum seekers from a given country of
origin lies above a given NNS value
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demonstrate how this can be achieved as a step towards
a (more) targeted and more efficient TB screening in
asylum seekers. Countries with indiscriminate screening
programmes should consider this evidence to enhance
the performance of their screening strategies.
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